Our future will be built on knowledge and experience.
About us: Management Team
The management team at Tangent Medical has extensive industry knowledge, experience, and success. They are committed and passionate about improving the safety and welfare of both patients and healthcare workers through the development of next-generation IV therapy products.
CEO and Chairman of the Board
A successful entrepreneurial executive, Jeff Williams joined Tangent Medical as CEO and Chairman of the Board in August 2011. Previously, he had been President and CEO of Accuri Cytometers, a life science instrument and clinical diagnostic company, from January 2010 until its sale to Becton, Dickinson and Company (NYSE: BDX) for $205M in March 2011. During his tenure at Accuri, Jeff oversaw year-over-year revenue growth of 65%, the development of a clinical system, and the achievement of positive cash flow. Prior to Accuri, he had been President and CEO of HandyLab, a molecular diagnostic company, since 2004. At HandyLab, Jeff led the growth and venture financing of the company, ultimately resulting in its sale for $275M in November 2009.
Prior to HandyLab, Jeff was President and CEO of Genomic Solutions Inc., a life science products company he co-founded in 1997. He led Genomic Solutions through a period of rapid growth culminating in an IPO on NASDAQ in 2000 and merger with Harvard Biosciences, Inc. in late 2002. Prior to Genomic Solutions, Jeff held executive and management level positions in several bioscience companies, including IRIS and Boehringer Mannheim. He received a BS in Biology from Alma College and a MBA from the University of Michigan.
Chief Financial Officer
Colleen Spencer has been the CFO for several medical device and technology start-ups, including HandyLab, Avail Networks and MCE Companies. Her tenure at these companies involved venture capital and bank financings, mezzanine financings and an initial public offering, in addition to investor relations and administrative responsibilities.
Prior to that, Colleen was Controller and Treasurer at a privately-held manufacturer for ten years. Before that she held a range of managerial positions at Arthur Anderson, including Audit Manager from 1983 to 1985, during which she managed the audits of many high-tech start-ups. She holds a BS in Business Administration from Central Michigan University and a MBA from the University of Michigan.
Jamie Olson joined Tangent Medical in August 2011 and is responsible for manufacturing, supply chain management, information technology and facilities management. Previously, Jamie was Director of Supply Chain Management and Information Technology at HandyLab from 2004 through its sale to BD in November 2009. He remained with BD until July 2011 to transition the manufacturing facility to BD locations.
From 1999 to 2004, Jamie held various senior manager roles in the Information Technology Program Management Office for MedImmune, a publicly-traded pharmaceutical company. Prior to MedImmune, Jamie spent nine years in the Diagnostics Division of the Bayer Corporation in materials management and production planning roles. He has a BS in Production and Operations Management from Western Illinois University and a MBA from the University of Indiana.
VP, Sales & Marketing
Curtis Bloch joined Tangent Medical as the VP Sales & Marketing in January 2012. Previously, he was Director of Marketing for BD Diagnostics, where he was responsible for the market development, integrated business strategies, and commercial execution of a product portfolio focused on hospital acquired infections. In his prior role as a Group Product Director for BD Medical, he managed a large portfolio of short-peripheral IV catheters, closed IV catheter systems, and extended dwell catheters which exceeded $300 million in revenue.
Curtis joined BD in 1996 and throughout his 15-year tenure, held a variety of sales, marketing, and management positions within medical devices. He has extensive knowledge and experience with healthcare worker and patient safety, and has demonstrated success in creating long-term growth strategies through high impact strategic marketing, new product development, and commercial execution.
Curtis started his career in pharmaceutical sales with The Upjohn Company. He received his BA in Business Administration from the University of San Diego.
Kay Fuller, RAC
VP Regulatory and Clinical Affairs
Kay Fuller has led successful global clinical studies and regulatory marketing authorization submissions for more than 35 Class II and Class III medical devices and combination products, via the US FDA IDE, IND, 510(k), PMA and European Union CE mark processes.
In 2010, she founded MDRS, LLC, a national regulatory consulting firm that specializes in providing strategic FDA and global regulatory, quality and clinical affairs support to biotechnology companies. Prior to establishing MDRS, she developed the IND/IDE Faculty Investigator Assistance Program (MIAP) at the University of Michigan (UM) Medical School’s Institute for Clinical and Health Research (MICHR). During her tenure at MICHR, she was an original member of the UM Medical Innovation Center Technical Advisory Group and an active member of the National NIH CTSA Regulatory Working Group IND/IDE Support Taskforce.
Prior to that, Kay held regulatory, quality, clinical and R&D management positions with global medical device companies, including W. L. Gore & Associates, P-S Medical (acquired by Medtronic), C. R. Bard, Cohera Medical and Terumo Corporation. She received her undergraduate degree in Veterinary Technology from Texas State Technical College and is board certified in Medical Device and Pharmaceutical Regulatory Affairs.